...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >A Randomized Controlled Trial of Intralesional Glucocorticoid for Treating Pretibial Myxedema
【24h】

A Randomized Controlled Trial of Intralesional Glucocorticoid for Treating Pretibial Myxedema

机译：糖皮质激素治疗胫前粘膜水肿的随机对照试验。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Pretibial myxedema (PTM) is an uncommon dermopathy associated with autoimmune thyroid diseases. Now it is thought to be autoimmune and its treatment with glucocorticoid is helpful. However, it has not been evaluated.Methods: A prospective randomized controlled trial was performed in 110 patients with PTM to evaluate the efficacy and safety of triamcinolone acetonide with intralesional injection once every 3 days and once every 7 days. Randomization was performed with drawing lots and it was also stratified according to variants of PTM lesions. In the follow-up, recurrent rates were observed. The SPSS Statistics 17.0 Software was used in the statistical analysis.Results: The complete response rates were 78.2%, 83.6%, and 87.3% in regimen 1 and 50.9%, 89.1%, and 90.9% in regimen 2 at 3 weeks, 7 weeks and the end of therapy, respectively. Regimen 1 had an earlier efficacy than regimen 2, but at 7 weeks and end of therapy, there were no differences between two regimens. The majority of non-severe variants got complete response but severe variants did not. The adverse reaction rates in regimen 1 were higher and earlier than those in regimen 2. Adverse reaction occurring time in regimen 1 was shorter than that in regimen 2. Recurrent rates were 31.25% and 32% in regimens 1 and 2 at 3.5-year follow-up.Conclusions: For its autoimmune, hyperplasia and disabled features, early treatment of PTM with glucocorticoid is necessary to get complete response. Dosage and frequency of intralesional steroid injection and lesional variants influence the efficacy of PTM. Once every 7 days is a better regimen.J Clin Med Res. 2015;7(11):862-872doi: http://dx.doi.org/10.14740/jocmr2303w
机译：背景：胫前粘膜水肿（PTM）是与自身免疫性甲状腺疾病相关的罕见皮肤病。现在人们认为它是自身免疫性的，用糖皮质激素治疗很有帮助。方法：对110例PTM患者进行前瞻性随机对照试验，评价每3天一次和每7天一次病灶内注射曲安奈德的疗效和安全性。随机抽签进行，也根据PTM病变的变体进行分层。在随访中，观察到复发率。结果使用SPSS Statistics 17.0软件进行统计分析。结果：在第3周，第7周，方案1的完全缓解率为78.2％，方案33.6％和87.3％，方案2的完全缓解率为50.9％，89.1％和90.9％。和治疗结束。方案1的疗效早于方案2，但在治疗7周和结束时，两种方案之间没有差异。大多数非严重变体都能完全缓解，但严重变体却没有。方案1的不良反应发生率高于方案2，并且早于方案2。方案1的不良反应发生时间比方案2短。在3.5年随访时，方案1和2的不良反应发生率分别为31.25％和32％。结论：由于其自身免疫性，增生性和残疾特征，早期使用糖皮质激素治疗PTM对于获得完全应答是必要的。病灶内类固醇注射的剂量和频率以及病灶变异会影响PTM的疗效。每7天一次是更好的疗程。JClin Med Res。 2015; 7（11）：862-872doi：http://dx.doi.org/10.14740/jocmr2303w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号